Earlier quoted context omitted.
If I understand the situation correctly, it seems fairly similar to the status quo with drugs, for better or worse. You can't patent chemicals naturally occurring in plants that have medicinal uses, but you can patent synthetic versions of the same drug.
I think you do understand it correctly, but I find it very disturbing. The difference between these two situations is night and day: the complete synthesis of naturally occurring small molecules is unique each time, and can require dozens of PhD-level chemists and a decade or more to complete, if it's even possible. It requires a huge amount of invention, and a huge amount of discovery. Making cDNA is a standard kit,…
Ease is not the question by which a patent is judged. When you do a PCR reaction, introns or not, you are creating a NEW molecule that didn't exist before. Period. If the judges are claiming that the "information content" is what counts, then that goes against the molecule-patenting precedent - it's really the "molecular identity" which should count.
Now, my preference is to not allow patenting - at all - but to be consistent with the existing patenting landscape, they should have allowed the myriad patents (except for the "method" of comparing a patient sequence with the reference sequence) to pass.